Jeffrey N Myers Selected Research

Squamous Cell Carcinoma of Head and Neck

4/2022	Induction chemotherapy with or without erlotinib in patients with head and neck squamous cell carcinoma amenable for surgical resection.
4/2022	Correction: Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck.
1/2022	Fusobacterium is enriched in oral cancer and promotes induction of programmed death-ligand 1 (PD-L1).
11/2021	Low doses of methylnaltrexone inhibits head and neck squamous cell carcinoma growth in vitro and in vivo by acting on the mu-opioid receptor.
8/2021	Mu-opioid receptor activation promotes in vitro and in vivo tumor growth in head and neck squamous cell carcinoma.
1/2021	Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck.
1/2021	Inclusion of extranodal extension in the lymph node classification of cutaneous squamous cell carcinoma of the head and neck.
1/2021	Combined Inhibition of Rad51 and Wee1 Enhances Cell Killing in HNSCC Through Induction of Apoptosis Associated With Excessive DNA Damage and Replication Stress.
1/2021	Outcomes of patients with oropharyngeal squamous cell carcinoma treated with induction chemotherapy followed by concurrent chemoradiation compared with those treated with concurrent chemoradiation.
1/2021	Cytotoxic and targeted systemic therapy in patients with advanced cutaneous squamous cell carcinoma in the head and neck.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jeffrey N Myers Research Topics

Disease

144	Neoplasms (Cancer) 01/2022 - 08/2002
93	Squamous Cell Carcinoma of Head and Neck 04/2022 - 12/2002
32	Neoplasm Metastasis (Metastasis) 12/2021 - 12/2002
28	Head and Neck Neoplasms (Head and Neck Cancer) 01/2022 - 08/2002
22	Squamous Cell Carcinoma (Epidermoid Carcinoma) 12/2021 - 08/2002
19	Mouth Neoplasms (Oral Cancer) 01/2022 - 08/2002
13	Anaplastic Thyroid Carcinoma 01/2019 - 12/2004
11	Carcinogenesis 11/2021 - 12/2006
11	Carcinoma (Carcinomatosis) 01/2021 - 03/2004
11	Melanoma (Melanoma, Malignant) 01/2017 - 03/2002
6	Lymphatic Metastasis 03/2013 - 04/2003
4	Adenoid Cystic Carcinoma (Cylindroma) 08/2019 - 01/2004
4	Hypoxia (Hypoxemia) 12/2015 - 09/2005
4	Thyroid Neoplasms (Thyroid Cancer) 04/2009 - 12/2004
3	Oropharyngeal Neoplasms 01/2021 - 11/2015
3	Mucositis 01/2021 - 11/2012
3	Squamous Cell Neoplasms (Squamous Cell Cancer) 01/2017 - 10/2009
2	Sinonasal undifferentiated carcinoma 10/2019 - 01/2016
2	Hematologic Neoplasms (Hematological Malignancy) 04/2018 - 03/2017
2	Extranodal Extension 01/2017 - 04/2003
2	Residual Neoplasm 03/2013 - 04/2006

Drug/Important Bio-Agent (IBA)

25	Proteins (Proteins, Gene)FDA Link 01/2021 - 11/2004
25	Biomarkers (Surrogate Marker)IBA 10/2020 - 02/2005
21	Cisplatin (Platino)FDA LinkGeneric 01/2021 - 11/2006
21	ErbB Receptors (EGF Receptor)IBA 01/2020 - 08/2002
13	Cetuximab (Erbitux)FDA Link 01/2021 - 01/2006
13	Paclitaxel (Taxol)FDA LinkGeneric 03/2012 - 08/2003
11	Pharmaceutical PreparationsIBA 05/2021 - 08/2011
11	Phosphotransferases (Kinase)IBA 01/2021 - 03/2005
9	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 11/2004
9	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 06/2007
8	Epidermal Growth Factor (EGF)IBA 05/2014 - 08/2002
8	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 04/2011 - 04/2005
7	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 04/2009 - 03/2005
6	Tyrosine Kinase InhibitorsIBA 11/2014 - 12/2005
6	AEE 788 (AEE788)IBA 11/2006 - 11/2004
5	Protons (Proton)IBA 01/2021 - 01/2017
5	Monoclonal AntibodiesIBA 01/2021 - 10/2008
5	Biological ProductsIBA 01/2021 - 12/2006
5	Docetaxel (Taxotere)FDA Link 12/2018 - 02/2013
5	LigandsIBA 12/2017 - 08/2006
5	vandetanib (ZD6474)IBA 03/2016 - 08/2008
4	Messenger RNA (mRNA)IBA 01/2022 - 10/2014
4	adavosertibIBA 01/2021 - 02/2015
4	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 12/2020 - 02/2005
4	MicroRNAs (MicroRNA)IBA 12/2020 - 11/2011
4	Metformin (Glucophage)FDA LinkGeneric 01/2016 - 01/2012
4	Fluorouracil (Carac)FDA LinkGeneric 07/2015 - 11/2012
4	Mitogen-Activated Protein KinasesIBA 06/2010 - 06/2005
4	Irinotecan (Camptosar)FDA LinkGeneric 08/2006 - 12/2005
3	RNA (Ribonucleic Acid)IBA 01/2022 - 01/2017
3	CarcinogensIBA 03/2021 - 01/2010
3	Immune Checkpoint InhibitorsIBA 01/2021 - 01/2017
3	Carboplatin (JM8)FDA LinkGeneric 01/2021 - 06/2010
3	Gefitinib (Iressa)FDA Link 01/2019 - 12/2004
3	EnzymesIBA 01/2016 - 02/2012
3	Bevacizumab (Avastin)FDA Link 12/2013 - 04/2007
3	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 04/2011 - 11/2004
3	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 06/2010 - 04/2006
3	CurcuminIBA 03/2010 - 09/2004
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 09/2005 - 11/2004
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 04/2022 - 11/2014
2	mu Opioid Receptors (mu Opioid Receptor)IBA 11/2021 - 08/2021
2	Nerve Growth Factor (NGF)IBA 01/2021 - 12/2020
2	Death Domain ReceptorsIBA 01/2021 - 12/2017
2	Adrenergic Agents (Adrenergic Drugs)IBA 01/2021 - 01/2020
2	niraparibIBA 01/2021 - 01/2020
2	Small Interfering RNA (siRNA)IBA 01/2021 - 01/2016
2	ParaffinIBA 10/2019 - 01/2014
2	Formaldehyde (Formol)FDA Link 10/2019 - 01/2014
2	TransferasesIBA 01/2019 - 01/2006
2	Annexin A5IBA 01/2019 - 09/2004
2	Fluorescein-5-isothiocyanate (FITC)IBA 01/2019 - 11/2011
2	Insulin-Like PeptidesIBA 01/2019 - 01/2006
2	AMP-Activated Protein KinasesIBA 01/2018 - 06/2014
2	Lactic Acid (Lactate)FDA LinkGeneric 03/2017 - 12/2015
2	Doxorubicin (Adriamycin)FDA LinkGeneric 03/2017 - 04/2007
2	PlatinumIBA 03/2017 - 04/2015
2	Cyclin D1IBA 10/2016 - 06/2013
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 09/2015 - 09/2005
2	Protein Kinases (Protein Kinase)IBA 07/2014 - 02/2011
2	Angiogenesis InhibitorsIBA 01/2014 - 04/2006
2	Interleukin-8 (Interleukin 8)IBA 08/2013 - 03/2005
2	Codon (Codons)IBA 06/2013 - 06/2010
2	Serine (L-Serine)FDA Link 06/2013 - 02/2011
2	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2013 - 09/2005

Therapy/Procedure

61	Therapeutics 01/2021 - 01/2002
31	Radiotherapy 01/2021 - 08/2003
15	Drug Therapy (Chemotherapy) 01/2021 - 04/2006
12	Neck Dissection (Radical Neck Dissection) 12/2021 - 12/2002
9	Induction Chemotherapy 04/2022 - 11/2012
6	Molecular Targeted Therapy 03/2011 - 08/2002
5	Chemoradiotherapy 01/2021 - 10/2009
3	Immunotherapy 04/2022 - 01/2017
3	Adjuvant Radiotherapy 02/2011 - 08/2003
3	Lasers (Laser) 10/2008 - 11/2004
2	Neoadjuvant Therapy 04/2022 - 06/2013
2	Aftercare (After-Treatment) 01/2021 - 09/2016
2	Laryngectomy 11/2020 - 01/2006
2	Free Tissue Flaps 06/2018 - 01/2006